AR132085A1 - Compuestos y su uso en el tratamiento del cáncer - Google Patents
Compuestos y su uso en el tratamiento del cáncerInfo
- Publication number
- AR132085A1 AR132085A1 ARP240100579A ARP240100579A AR132085A1 AR 132085 A1 AR132085 A1 AR 132085A1 AR P240100579 A ARP240100579 A AR P240100579A AR P240100579 A ARP240100579 A AR P240100579A AR 132085 A1 AR132085 A1 AR 132085A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- atom
- framework
- atoms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde: X¹ es CH o N; p es 0, 1 o 2; donde: cada R¹ es un sustituyente en cualquier átomo de C y se selecciona independientemente de F, Cl, alquilo C₁₋₃ y alcoxi C₁₋₃, en donde el alquilo C₁₋₃ y alcoxi C₁₋₃ pueden estar opcionalmente sustituidos de forma independiente por uno o más F; RN se selecciona de H y Me; n es 0, 1 o 2; m es 0 o 1; Q¹ es CH o N; cuando n y m son ambos distintos de 0, Q² es CH o N; cuando n y m son ambos 0, Q² es CH; cuando n es 0 o 1, Q³ es CH; cuando n es 2 y Q² es N, Q³ es CH; cuando n es 2 y Q² es CH, Q³ es CH u O; R²ᵃ y R²ᵇ son sustituyentes en átomos de C iguales o diferentes que no sean en Q¹ o Q², cada uno seleccionado independientemente de H, F y alquilo C₁₋₃, o R²ᵃ y R²ᵇ forman conjuntamente un grupo -(CH₂)ʳ- donde r es 1, 2 o 3; Q⁴ es un enlace individual o -NR⁴C(=O); R⁴ es H o Me; 0, 1 o 2 de Y¹, Y², Y³, Y⁴ e Y⁵ es / son N, y son de otro modo C; cada R³ es un sustituyente en cualquier átomo de C en Y¹, Y², Y³, Y⁴ e Y⁵, y se selecciona independientemente de F, Cl, CN, alquilo C₁₋₃ y alcoxi C₁₋₃, en donde el alquilo C₁₋₃ y alcoxi C₁₋₃ pueden estar opcionalmente sustituidos de forma independiente por uno o más F; q es 0, 1 o 2; en donde el Ligador está unido a cualquier átomo de C disponible en Y⁴ e Y⁵; el Ligador es un marco saturado o parcial o completamente no saturado que comprende átomos de C y H y al menos un heteroátomo, en donde dicho marco tiene puntos finales de unión a y b y una longitud de 5 a 26 átomos entre a y b; en donde dicho marco puede incluir una o más cadenas y/o anillos rectos y/o ramificados y se sustituye opcionalmente en cualquier átomo o átomos de C disponibles por uno o más F; y W es una unidad de unión a cereblón de ubiquitina-ligasa E3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363489528P | 2023-03-10 | 2023-03-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132085A1 true AR132085A1 (es) | 2025-05-21 |
Family
ID=90364229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100579A AR132085A1 (es) | 2023-03-10 | 2024-03-08 | Compuestos y su uso en el tratamiento del cáncer |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP4676922A1 (es) |
| JP (1) | JP2026510359A (es) |
| KR (1) | KR20250154418A (es) |
| CN (1) | CN120835881A (es) |
| AR (1) | AR132085A1 (es) |
| AU (1) | AU2024235906A1 (es) |
| CL (1) | CL2025002736A1 (es) |
| CO (1) | CO2025013819A2 (es) |
| CR (1) | CR20250426A (es) |
| DO (1) | DOP2025000220A (es) |
| IL (1) | IL323195A (es) |
| MX (1) | MX2025010560A (es) |
| PE (1) | PE20252537A1 (es) |
| TW (1) | TW202502749A (es) |
| UY (1) | UY40670A (es) |
| WO (1) | WO2024189488A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250197411A1 (en) | 2023-12-14 | 2025-06-19 | Astrazeneca Ab | Irak4 protacs |
| WO2026120044A1 (en) * | 2024-12-04 | 2026-06-11 | Astrazeneca Ab | Smarca2 degraders and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3526202T1 (sl) | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| EP3795570B1 (en) * | 2019-09-23 | 2022-02-23 | Accutar Biotechnology Inc. | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof |
| WO2021061644A1 (en) * | 2019-09-23 | 2021-04-01 | Accutar Biotechnology Inc. | Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof |
| WO2021231927A1 (en) * | 2020-05-14 | 2021-11-18 | The Regents Of The University Of Michigan | Androgen receptor protein degraders with a tricyclic cereblon ligand |
-
2024
- 2024-03-08 JP JP2025552091A patent/JP2026510359A/ja active Pending
- 2024-03-08 CR CR20250426A patent/CR20250426A/es unknown
- 2024-03-08 WO PCT/IB2024/052251 patent/WO2024189488A1/en not_active Ceased
- 2024-03-08 TW TW113108535A patent/TW202502749A/zh unknown
- 2024-03-08 AR ARP240100579A patent/AR132085A1/es unknown
- 2024-03-08 CN CN202480017738.0A patent/CN120835881A/zh active Pending
- 2024-03-08 AU AU2024235906A patent/AU2024235906A1/en active Pending
- 2024-03-08 EP EP24711274.1A patent/EP4676922A1/en active Pending
- 2024-03-08 KR KR1020257030598A patent/KR20250154418A/ko active Pending
- 2024-03-08 PE PE2025001965A patent/PE20252537A1/es unknown
- 2024-03-11 UY UY0001040670A patent/UY40670A/es unknown
-
2025
- 2025-09-07 IL IL323195A patent/IL323195A/en unknown
- 2025-09-08 MX MX2025010560A patent/MX2025010560A/es unknown
- 2025-09-08 DO DO2025000220A patent/DOP2025000220A/es unknown
- 2025-09-09 CL CL2025002736A patent/CL2025002736A1/es unknown
- 2025-10-06 CO CONC2025/0013819A patent/CO2025013819A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250154418A (ko) | 2025-10-28 |
| MX2025010560A (es) | 2025-10-01 |
| TW202502749A (zh) | 2025-01-16 |
| DOP2025000220A (es) | 2025-10-31 |
| UY40670A (es) | 2024-09-13 |
| CL2025002736A1 (es) | 2026-01-02 |
| IL323195A (en) | 2025-11-01 |
| AU2024235906A1 (en) | 2025-10-30 |
| EP4676922A1 (en) | 2026-01-14 |
| PE20252537A1 (es) | 2025-10-27 |
| CR20250426A (es) | 2025-11-21 |
| CO2025013819A2 (es) | 2025-10-20 |
| JP2026510359A (ja) | 2026-04-02 |
| WO2024189488A1 (en) | 2024-09-19 |
| CN120835881A (zh) | 2025-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112338A2 (es) | Arilciclohexiléteres de dihidro-tetraazabenzoazuleno | |
| AR119018A1 (es) | Inhibidores de proteína quinasas dependientes de adn | |
| AR071792A1 (es) | Antagonistas nitrogenados del receptor de glucagon, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de la diabetes tipo ii y afecciones relacionadas. | |
| AR088000A1 (es) | Derivados de pirazolquinolinona, su preparacion y su uso terapeutico | |
| AR104720A1 (es) | Moduladores de ccr2 | |
| AR091962A1 (es) | Compuesto antidiabeticos triciclicos | |
| AR098912A1 (es) | Inhibidores de syk | |
| AR111850A1 (es) | Trifluorometiloxadiazoles sustituidos para combatir hongos fitopatógenos | |
| AR057626A1 (es) | Derivados de pirido pirazo y pirimido- pirimidina y su uso como inhibidores de mtor | |
| ES2662397T3 (es) | Inhibidores de la quinasa reguladora de la señal de apoptosis | |
| AR112392A1 (es) | Compuesto tricíclico de pirazol, su uso para fabricar un medicamento y composición farmaceutica que lo comprende | |
| AR092269A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| CO6280476A2 (es) | Derivados de alcanos azabiciclicos sustituidos con biarilo como moduladores de la actividad de los receptores nicotinicos de acetilcolina | |
| AR063800A1 (es) | Derivados de acido nicotinico, composiciones farmaceuticas que las contienen y metodos de uso de los mismos | |
| AR080467A1 (es) | Derivados tetrazolicos moduladores selectivos de receptores cb2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor y otras enfermedades | |
| ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
| AR107955A1 (es) | Derivados de piridino- / pirimidino-piridina, con actividad herbicida | |
| AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR116474A1 (es) | DERIVADOS DEL ÁCIDO 6,7-DIHIDRO-2H-BENZOFURO[2,3-a]QUINOLIZIN-3-CARBOXÍLICO COMO AGENTES ANTIVIRALES PARA EL TRATAMIENTO O PREVENCIÓN DE UNA INFECCIÓN POR HBV | |
| AR098818A1 (es) | Derivados de oxindol, preparación de los mismos y uso terapéutico de los mismos | |
| AR122007A1 (es) | Inhibidores de il4i1 y métodos de uso | |
| PE20241934A1 (es) | Inhibidores de raf quinasa y metodos de uso de los mismos | |
| AR096161A1 (es) | Derivados de triazina | |
| AR128314A1 (es) | Compuestos y su uso en el tratamiento del cáncer |